文献速递妇科

西米普利单抗治疗复发或转移性宫颈癌:I期扩展队列数据及宫颈癌PD-L1表达特征分析

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
PubMed 文献 · Gynecol Oncol · 2020-09-09

在非随机I期扩展队列中,20例复发或转移性宫颈癌患者接受西米普利单抗单药或联合大分割放疗,两个队列客观缓解率均为10%,缓解者均为鳞癌;腺癌的PD-L1蛋白和mRNA表达低于鳞癌。

要点

  • 西米普利单抗在宫颈鳞癌中具有抗肿瘤活性。
  • 单药和联合大分割放疗队列客观缓解率均为10%。
  • 腺癌PD-L1蛋白表达阴性和mRNA水平低于鳞癌。

核心结论

  • 西米普利单抗在宫颈鳞状细胞癌中具有活性。
  • I期结果结合其他抗PD-1试验及生物标志物分析,为正在进行的III期试验设计提供了依据,该试验的主要总生存分层分析首先在鳞癌组织学患者中进行。

研究设计与样本

  • 非随机I期扩展队列研究,共入组20例复发或转移性宫颈癌患者,其中10例为鳞癌组织学。
  • 患者接受西米普利单抗3 mg/kg静脉给药,每2周一次,持续48周,单药队列单独用药,联合队列在第2周联合大分割放疗。
  • PD-L1蛋白表达在商业购买的样本中评估,mRNA表达水平从癌症基因组图谱(TCGA)分析。

主要发现

  • 任何级别最常见的不良事件为腹泻、疲乏和低钾血症,发生率分别为35%、25%和25%。
  • 单药队列和联合队列的客观缓解率均为10%,缓解者均为鳞癌组织学。
  • 单药队列和联合队列缓解者的缓解持续时间分别为11.2个月和6.4个月。
  • 在单独存档标本(N=155)中,腺癌的肿瘤和免疫细胞PD-L1蛋白表达阴性(<1%)比鳞癌更常见。
  • TCGA中腺癌的PD-L1 mRNA水平低于鳞状细胞肿瘤,平均每百万转录本分别为1.2 vs 5.0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于组织材料不足,PD-L1蛋白表达在商业购买的样本中评估,mRNA表达水平从TCGA分析。
  • 受照射病灶未纳入缓解评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients with recurrent or metastatic cervical cancer. To determine the association between histology and programmed death-ligand 1 (PD-L1) expression. METHODS: In non-randomized phase I expansion cohorts, patients (squamous or non-squamous histology) received cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks, either alone (monotherapy cohort) or with hfRT during week 2 (combination cohort). Due to insufficient tissue material, PD-L1 protein expression was evaluated in commercially purchased samples and mRNA expression levels were analyzed from The Cancer Genome Atlas (TCGA). RESULTS: Twenty patients enrolled in both cohorts in total; 10 had squamous histology. The most common adverse events of any grade were diarrhea, fatigue, and hypokalemia, occurring in 35%, 25%, and 25%, respectively. Objective response rate was 10% in each cohort; responders had squamous histology. Duration of response was 11.2 months and 6.4 months for the responder in the monotherapy and combination cohort, respectively. Irradiated lesions were not included in the response assessments. In separate archived specimens (N = 155), PD-L1 protein expression in tumor and immune cells was negative (<1%) more commonly in adenocarcinoma than in squamous tumors. PD-L1 mRNA levels were lower in adenocarcinoma than squamous cell tumors (1.2 vs 5.0 mean transcripts per million, respectively) in TCGA. CONCLUSIONS: Cemiplimab has activity in cervical squamous cell carcinoma. The phase I results, combined with results from other anti-PD-1 trials in cervical cancer and our biomarker analyses have informed the design of the ongoing phase III trial, with the primary overall survival hierarchical analyses being done first in patients with squamous histology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rischin D, Gil-Martin M, González-Martin A, et al. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020. PMID: 32917410. doi:10.1016/j.ygyno.2020.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。